Adma Biologics Inc - Understand $adma stock

$ADMA Market Cap: $4.361 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$330.2M

TTM

Gross Margin

45.02%

TTM

Net Earnings

$34.79M

TTM

Current Assets

$303.7M

Q2 2024

Current Liabilities

$44.20M

Q2 2024

Current Ratio

687.08%

Q2 2024

Total Assets

$376.4M

Q2 2024

Total Liabilities

$188.1M

Q2 2024

Book Value

$188.3M

Q2 2024

Cash

$88.20M

Q2 2024

P/E

125.4

Sep 17, 2024 EST

Free Cash Flow

$66.13M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	$258.2M	$154.1M	$80.94M	$42.22M	$29.35M	$16.99M	$22.76M	$10.66M	$7.180M	$5.920M	$3.070M	$1.120M	$760.0K	$0.00
YoY Change	67.59%	90.36%	91.72%	43.85%	72.74%	-25.35%	113.51%	48.47%	21.28%	92.83%	174.11%	47.37%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	$258.2M	$154.1M	$80.94M	$42.22M	$29.35M	$16.99M	$22.76M	$10.66M	$7.180M	$5.920M	$3.070M	$1.120M	$760.0K	$0.00
Cost Of Revenue	$169.3M	$118.8M	$79.77M	$61.29M	$39.50M	$42.19M	$29.16M	$6.360M	$4.310M	$3.740M	$2.020M	$670.0K	$2.140M	$0.00
Gross Profit	$88.94M	$35.27M	$1.173M	-$19.07M	-$10.16M	-$25.21M	-$6.400M	$4.300M	$2.870M	$2.170M	$1.040M	$450.0K	-$1.380M	$0.00
Gross Profit Margin	34.44%	22.89%	1.45%	-45.17%	-34.6%	-148.38%	-28.12%	40.34%	39.97%	36.66%	33.88%	40.18%	-181.58%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Selling, General & Admin	$59.02M	$52.46M	$42.90M	$35.05M	$28.08M	$30.31M	$24.60M	$13.94M	$11.36M	$8.670M	$6.780M	$4.890M	$2.600M	$3.300M
YoY Change	12.51%	22.29%	22.38%	24.82%	-7.36%	23.21%	76.47%	22.71%	31.03%	27.88%	38.65%	88.08%	-21.21%
% of Gross Profit	66.36%	148.75%	3656.14%					324.19%	395.82%	399.54%	651.92%	1086.67%
Research & Development	$3.300M	$3.614M	$3.646M	$5.907M	$2.344M	$3.930M	$6.230M	$7.690M	$7.020M	$9.520M	$9.300M	$3.470M	$650.0K	$2.190M
YoY Change	-8.68%	-0.89%	-38.28%	152.02%	-40.36%	-36.92%	-18.99%	9.54%	-26.26%	2.37%	168.01%	433.85%	-70.32%
% of Gross Profit	3.71%	10.25%	310.76%					178.84%	244.6%	438.71%	894.23%	771.11%
Depreciation & Amortization	$7.600M	$6.400M	$4.800M	$3.200M	$2.400M	$3.450M	$2.690M	$470.0K	$470.0K	$250.0K	$210.0K	$180.0K	$220.0K	$220.0K
YoY Change	18.75%	33.33%	50.0%	33.33%	-30.43%	28.25%	472.34%	0.0%	88.0%	19.05%	16.67%	-18.18%	0.0%
% of Gross Profit	8.54%	18.15%	409.11%					10.93%	16.38%	11.52%	20.19%	40.0%
Operating Expenses	$67.31M	$74.63M	$59.55M	$45.84M	$70.77M	$35.08M	$32.06M	$21.63M	$18.38M	$18.19M	$16.09M	$8.360M	$3.240M	$5.500M
YoY Change	-9.81%	25.33%	29.89%	-35.23%	101.75%	9.42%	48.22%	17.68%	1.04%	13.05%	92.46%	158.02%	-41.09%
Operating Profit	$21.63M	-$39.37M	-$58.37M	-$64.91M	-$41.42M	-$60.29M	-$38.46M	-$17.33M	-$15.51M	-$16.02M	-$15.05M	-$7.910M	-$4.620M	-$5.500M
YoY Change	-154.95%	-32.56%	-10.08%	56.71%	-31.29%	56.76%	121.93%	11.73%	-3.18%	6.45%	90.27%	71.21%	-16.0%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Interest Expense	$25.03M	$19.28M	$13.06M	$11.99M	$8.993M	-$5.330M	-$3.230M	-$2.190M	-$1.740M	-$1.350M	-$570.0K	-$10.00K	-$1.600M	-$700.0K
YoY Change	29.81%	47.66%	8.94%	33.27%	-268.73%	65.02%	47.49%	25.86%	28.89%	136.84%	5600.0%	-99.38%	128.57%
% of Operating Profit	115.69%
Other Income/Expense, Net	-$49.87M	-$26.54M	-$13.27M	-$10.83M	-$6.855M	-$130.0K	-$10.00K	$0.00		$0.00	$80.00K			$240.0K
YoY Change	87.92%	99.93%	22.52%	58.04%	5173.07%	1200.0%				-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Pretax Income	-$28.24M	-$65.90M	-$71.65M	-$75.75M	-$48.28M	-$65.74M	-$43.76M	-$19.52M	-$17.97M	-$17.36M	-$15.53M	-$7.920M	-$6.220M	-$5.950M
YoY Change	-57.15%	-8.02%	-5.42%	56.9%	-26.56%	50.23%	124.18%	8.63%	3.51%	11.78%	96.09%	27.33%	4.54%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00	-$550.0K	$0.00	-$620.0K	-$320.0K	$0.00
% Of Pretax Income
Net Earnings	-$28.24M	-$65.90M	-$71.65M	-$75.75M	-$48.28M	-$65.74M	-$43.76M	-$19.52M	-$17.97M	-$16.81M	-$15.53M	-$7.300M	-$5.900M	-$5.950M
YoY Change	-57.15%	-8.02%	-5.41%	56.9%	-26.56%	50.23%	124.18%	8.63%	6.9%	8.24%	112.74%	23.73%	-0.84%
Net Earnings / Revenue	-10.94%	-42.77%	-88.52%	-179.41%	-164.5%	-386.93%	-192.27%	-183.11%	-250.28%	-283.95%	-505.86%	-651.79%	-776.32%
Basic Earnings Per Share	-$0.13	-$0.33	-$0.51	-$0.88
Diluted Earnings Per Share	-$0.13	-$0.33	-$0.51	-$0.88	-$888.3K	-$1.455M	-$1.911M	-$1.607M	-$1.726M	-$1.809M	-$2.378M	-$1.385M	-$1.934M	-$2.490M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Cash & Short-Term Investments	$51.35M	$86.52M	$51.09M	$55.90M	$26.80M	$22.80M	$43.10M	$15.30M	$16.80M	$21.90M	$29.10M	$12.50M	$100.0K	$200.0K
YoY Change	-40.65%	69.35%	-8.61%	108.58%	17.54%	-47.1%	181.7%	-8.93%	-23.29%	-24.74%	132.8%	12400.0%	-50.0%
Cash & Equivalents	$51.35M	$86.52M	$51.09M	$55.90M	$26.80M	$22.80M	$43.10M	$9.900M	$10.40M	$17.20M	$26.10M	$12.50M	$100.0K	$200.0K
Short-Term Investments								$5.400M	$6.400M	$4.700M	$2.900M
Other Short-Term Assets	$5.334M	$5.095M	$4.339M	$3.000M	$2.500M	$1.800M	$2.700M	$300.0K	$100.0K	$100.0K	$300.0K	$100.0K	$100.0K	$100.0K
YoY Change	4.69%	17.42%	44.64%	20.0%	38.89%	-33.33%	800.0%	200.0%	0.0%	-66.67%	200.0%	0.0%	0.0%
Inventory	$172.9M	$163.3M	$124.7M	$81.50M	$53.10M	$18.60M	$12.60M	$5.000M	$3.400M	$1.700M	$1.700M	$1.300M	$1.100M	$3.400M
Prepaid Expenses
Receivables	$27.42M	$15.51M	$28.58M	$13.20M	$3.500M	$1.400M	$3.900M	$1.000M	$900.0K	$400.0K	$0.00	$0.00	$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$257.0M	$270.4M	$208.7M	$153.7M	$85.80M	$44.50M	$62.30M	$21.70M	$21.30M	$24.10M	$31.10M	$13.90M	$1.300M	$3.700M
YoY Change	-4.95%	29.55%	35.8%	79.14%	92.81%	-28.57%	187.1%	1.88%	-11.62%	-22.51%	123.74%	969.23%	-64.86%
Property, Plant & Equipment	$63.47M	$68.75M	$58.20M	$45.90M	$33.10M	$30.10M	$30.50M	$2.000M	$2.400M	$2.800M	$800.0K	$800.0K	$900.0K	$1.100M
YoY Change	-7.68%	18.13%	26.79%	38.67%	9.97%	-1.31%	1425.0%	-16.67%	-14.29%	250.0%	0.0%	-11.11%	-18.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments											$0.00	$500.0K	$300.0K	$400.0K
YoY Change											-100.0%	66.67%	-25.0%
Other Assets	$4.670M	$4.770M	$4.067M	$2.100M	$1.400M	$6.700M	$6.800M	$0.00	$0.00	$100.0K	$200.0K	$400.0K	$400.0K	$0.00
YoY Change	-2.1%	17.28%	93.69%	50.0%	-79.1%	-1.47%			-100.0%	-50.0%	-50.0%	0.0%
Total Long-Term Assets	$72.17M	$78.06M	$67.52M	$54.00M	$41.30M	$44.40M	$45.70M	$2.000M	$2.400M	$2.900M	$900.0K	$1.700M	$1.600M	$1.500M
YoY Change	-7.55%	15.6%	25.04%	30.75%	-6.98%	-2.84%	2185.0%	-16.67%	-17.24%	222.22%	-47.06%	6.25%	6.67%
Total Assets	$329.2M	$348.5M	$276.3M	$207.7M	$127.1M	$88.90M	$108.0M	$23.70M	$23.70M	$27.00M	$32.00M	$15.60M	$2.900M	$5.200M
YoY Change
Accounts Payable	$15.66M	$13.23M	$12.43M	$11.10M	$9.200M	$5.900M	$5.900M	$2.600M	$2.100M	$1.800M	$2.700M	$1.100M	$1.300M	$800.0K
YoY Change	18.37%	6.44%	11.98%	20.65%	55.93%	0.0%	126.92%	23.81%	16.67%	-33.33%	145.45%	-15.38%	62.5%
Accrued Expenses	$31.05M	$24.10M	$16.79M	$8.700M	$4.700M	$3.600M	$3.400M	$2.400M	$2.000M	$2.300M	$900.0K	$700.0K	$500.0K	$900.0K
YoY Change	28.86%	43.5%	93.04%	85.11%	30.56%	5.88%	41.67%	20.0%	-13.04%	155.56%	28.57%	40.0%	-44.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due								$6.100M	$0.00	$0.00	$0.00	$0.00	$500.0K	$7.100M
YoY Change												-100.0%	-92.96%
Total Short-Term Liabilities	$49.81M	$39.27M	$30.38M	$19.90M	$14.00M	$9.600M	$9.400M	$11.20M	$4.200M	$4.200M	$3.700M	$1.800M	$2.300M	$8.900M
YoY Change	26.84%	29.26%	52.65%	42.14%	45.83%	2.13%	-16.07%	166.67%	0.0%	13.51%	105.56%	-21.74%	-74.16%
Long-Term Debt	$130.6M	$142.8M	$94.87M	$93.00M	$83.20M	$44.10M	$43.00M	$14.10M	$15.70M	$15.20M	$5.100M	$4.200M	$100.0K	$100.0K
YoY Change	-8.57%	50.56%	2.01%	11.78%	88.66%	2.56%	204.96%	-10.19%	3.29%	198.04%	21.43%	4100.0%	0.0%
Other Long-Term Liabilities	$13.58M	$14.39M	$9.836M	$6.500M	$3.700M	$15.40M	$15.30M	$2.800M	$3.000M	$1.600M	$1.700M	$100.0K	$100.0K	$200.0K
YoY Change	-5.64%	46.28%	51.32%	75.68%	-75.97%	0.65%	446.43%	-6.67%	87.5%	-5.88%	1600.0%	0.0%	-50.0%
Total Long-Term Liabilities	$144.2M	$157.2M	$104.7M	$99.50M	$86.90M	$59.50M	$58.30M	$16.90M	$18.70M	$16.80M	$6.800M	$4.300M	$200.0K	$300.0K
YoY Change	-8.3%	50.16%	5.23%	14.5%	46.05%	2.06%	244.97%	-9.63%	11.31%	147.06%	58.14%	2050.0%	-33.33%
Total Liabilities	$194.0M	$196.5M	$135.1M	$119.4M	$100.9M	$69.10M	$67.70M	$28.10M	$22.90M	$21.00M	$10.40M	$6.100M	$2.500M	$9.100M
YoY Change	-1.28%	45.46%	13.13%	18.33%	46.02%	2.07%	140.93%	22.71%	9.05%	101.92%	70.49%	144.0%	-72.53%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	224.0M	197.9M	139.6M	86.15M
Diluted Shares Outstanding	224.0M	197.9M	139.6M	86.15M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $4.361 Billion

About ADMA Biologics Inc

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 624 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Industry: Biological Products, (No Diagnostic Substances) Peers: Alaunos Therapeutics Inc Allakos Inc Aura Biosciences Inc Entrada Therapeutics Inc Imago BioSciences, Inc. Precigen Inc Lexicon Pharmaceuticals Inc Rallybio Corp